Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson's disease

SJ Miller, RY Darji, S Walaieh, JA Lewis… - Frontiers in …, 2023 - frontiersin.org
Drosophila melanogaster is a valuable model organism for a wide range of biological
exploration. The well-known advantages of D. melanogaster include its relatively simple …

Senolytics: opening avenues in drug discovery to find novel therapeutics for Parkinson's disease

V Kakoty, SK Chandran, M Gulati, BH Goh, K Dua… - Drug Discovery …, 2023 - Elsevier
Highlights•Parkinson's Disease (PD) affects motor functions of individual.•Accumulation of
senescent cells (SC) deteriorate the pathological cascade of PD.•SC secrete components …

[HTML][HTML] Disease model organism for Parkinson disease: Drosophila melanogaster

B Aryal, Y Lee - BMB reports, 2019 - ncbi.nlm.nih.gov
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by
selective and progressive loss of dopaminergic neurons. Genetic and environmental risk …

Mechanisms of Parkinson's disease: lessons from Drosophila

VL Hewitt, AJ Whitworth - Current topics in developmental biology, 2017 - Elsevier
The power of Drosophila genetics has attracted attention in tackling important biomedical
challenges such as the understanding and prevention of neurodegenerative diseases …

[图书][B] Understanding Pathophysiology of Sporadic Parkinson's Disease in Drosophila Model: Potential Opportunities and Notable Limitations

P Modi, A Mohamad, L Phom, Z Koza, A Das… - 2016 - books.google.com
Parkinson's disease (PD) is the second most common neurodegenerative disorder affecting
approximately 1% of the population over age 50. PD is widely accepted as a multifactorial …

Adult health and transition stage-specific rotenone-mediated Drosophila model of Parkinson's disease: Impact on late-onset neurodegenerative disease models

M Ayajuddin, L Phom, Z Koza, P Modi, A Das… - Frontiers in molecular …, 2022 - frontiersin.org
Parkinson's disease (PD) affects almost 1% of the population worldwide over the age of 50
years. Exposure to environmental toxins like paraquat and rotenone is a risk factor for …

Drosophila models pioneer a new approach to drug discovery for Parkinson's disease

AJ Whitworth, PD Wes, LJ Pallanck - Drug discovery today, 2006 - Elsevier
Despite the prevalence and severity of Parkinson's disease (PD), little is known about the
molecular etiology of this disease, and preventative and disease-modifying therapies remain …

Modeling Parkinson's disease in adult Drosophila

L Dabool, L Juravlev, K Hakim-Mishnaevski… - Journal of Neuroscience …, 2019 - Elsevier
Background Protein aggregation in neurons is a prominent pathological mark of
neurodegeneration. In Parkinson's disease (PD), inclusions of the α-Synuclein (α-Syn) …

Promising rodent models in Parkinson's disease

P Imbriani, G Sciamanna, M Santoro, T Schirinzi… - Parkinsonism & related …, 2018 - Elsevier
Background In the past decade, the study of the pathogenic mechanisms underlying
neurodegeneration in Parkinson's disease (PD) has revealed a genetic component, often …

Non-mammalian animal models of Parkinson's disease for drug discovery

KL Lim - Expert Opinion on Drug Discovery, 2010 - Taylor & Francis
Importance of the field: Parkinson's disease (PD) is a prevalent neurodegenerative disease
affecting millions of predominantly elderly individuals worldwide. Despite intensive efforts …